Montrouge, France

Gilles Avenard

This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Acticor Biotech, Universite Paris-Xiii, Inserm (Institut National De La Santé Et De La Recherche Médicale). Active years: 2023-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gilles Avenard. Retrieved from https://idiyas.com/inventor/gilles-avenard

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2023-2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Gilles Avenard

Introduction

Gilles Avenard is a notable inventor based in Montrouge, France. He has made significant contributions to the field of biotechnology, particularly in the area of platelet aggregation. His work has implications for treating various medical conditions related to Glycoprotein VI.

Latest Patents

Avenard holds a patent titled "Inhibition of platelet aggregation using anti-human GPVI antibodies." This invention involves an isolated humanized protein that binds to human Glycoprotein VI (hGPVI) for treating GPVI-related conditions. The isolated humanized protein is designed to be administered to a subject for a duration of at least 2 hours, preferably between 4 to 6 hours.

Career Highlights

Throughout his career, Gilles Avenard has worked with prominent organizations such as Acticor Biotech and Université Paris Cité. His experience in these institutions has allowed him to advance his research and contribute to innovative solutions in the medical field.

Collaborations

Avenard has collaborated with esteemed colleagues, including Philippe Billiald and Martine Jandrot-Perrus. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking inventions.

Conclusion

Gilles Avenard's work exemplifies the impact of innovation in biotechnology. His patent on inhibiting platelet aggregation showcases his commitment to advancing medical treatments. Through his career and collaborations, Avenard continues to contribute to significant advancements in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…